Generation of Donor-specific T Regulatory Type 1 Cells From Patients on Dialysis for Cell Therapy After Kidney Transplantation.

Transplantation

1 Transplant Unit, Ospedale San Raffaele, Milan, Italy. 2 Currently, Laboratory for Translational Immunology, Universiteit Medisch Centrum Utrecht, Utrecht, The Netherlands; formerly, Diabetes Research Institute IRCCS San Raffaele Scientific Institute, Milan, Italy. 3 Diabetes Research Institute IRCCS San Raffaele Scientific Institute, Milan, Italy. 4 Nephrology and Dialysis Unit, Ospedale San Raffaele, Milan, Italy. 5 Universita' Vita-Salute San Raffaele, Milan, Italy.

Published: August 2015

Background: T regulatory type 1 (Tr1) cell-mediated induction of tolerance in preclinical models of transplantation is remarkably effective. The clinical application of such a therapy in patients on dialysis undergoing kidney transplantation should take into account the possible alterations of the immune system observed in these patients. Herein, we aimed at testing the ability to generate donor-specific Tr1 cell-enriched lymphocytes from patients on dialysis on the waiting list for kidney transplantation.

Methods: The Tr1 cell-enriched lymphocytes were generated by coculturing interleukin-10-producing dendritic cells obtained from healthy donors with peripheral blood mononuclear cells (PBMCs) of patients on dialysis, following the same protocol used in a previous cell therapy clinical trial to prevent graft-versus-host disease. Alternatively, purified CD4(+) T cells were used instead of total PBMCs. The ability to generate clinical-grade Tr1 cell-enriched products was defined by testing the reduced response to restimulation with mature dendritic cells generated from the original donor (i.e., anergy assay).

Results: The Tr1 cell-enriched medicinal products generated from PBMCs of patients on dialysis showed a low anergic phenotype, incompatible with their eventual clinical application. This was irrespective of HLA matching with the donor or the intrinsically reduced ability to proliferate in response to alloantigens. On the contrary, the use of purified CD4(+) T cells isolated from patients on dialysis led to the generation of a highly anergic donor-specific medicinal product containing an average of 10% Tr1 cells.

Conclusions: The Tr1 cell-enriched medicinal products can be efficiently generated from patients on dialysis by carefully tailoring the protocol on the patients' immunological characteristics.

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0000000000000751DOI Listing

Publication Analysis

Top Keywords

patients dialysis
28
tr1 cell-enriched
20
regulatory type
8
patients
8
cell therapy
8
kidney transplantation
8
clinical application
8
ability generate
8
cell-enriched lymphocytes
8
dendritic cells
8

Similar Publications

Liver assistive devices in acute liver failure: Current use and future directions.

Best Pract Res Clin Gastroenterol

December 2024

Department of Critical Care Medicine, University of Alberta, Edmonton, Canada; Division of Gastroenterology (Liver Unit), University of Alberta, Edmonton, Canada. Electronic address:

Article Synopsis
  • * The only certain treatment for ALF is liver transplantation (LT); however, some patients, especially those with acetaminophen-related liver failure, might recover with medical support instead of needing LT.
  • * Extracorporeal liver support (ECLS) is a growing area of interest in treating ALF, aiming to help the liver by removing toxins and promoting regeneration, with two main types: artificial ECLS (like dialysis methods) and bioartificial ECLS (which uses live hepat
View Article and Find Full Text PDF

Therapeutic plasma exchange (PLEX) is an adjunctive treatment for patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and kidney involvement. Little is known about the effect of PLEX on early changes in kidney function. This post-hoc analysis of the PEXIVAS trial investigated the effects of PLEX on changes in kidney function within 12 months.

View Article and Find Full Text PDF

Background: There remains a paucity of data regarding the cardio-renal benefits of sodium-glucose co-transporter-2 inhibitors (SGLT2i) in patients with chronic kidney disease stage 5 (CKD V) based on major clinical trials.

Objective: This retrospective study aimed to identify potential cardiovascular and renal outcomes associated with SGLT2i use in CKD V patients.

Methods: We queried the TriNetX Global collaborative network from Jan 2014 - Aug 2023 for patients ≥18 years diagnosed with CKD V but not on dialysis.

View Article and Find Full Text PDF

Various aggressive lymphomas entities have been associated with immunodeficiency. To provide further evidence that also MYC-negative high-grade B-cell (formerly Burkitt-like) lymphoma with 11q aberrations comprises an immunodeficiency-related subtype, we here conducted a comprehensive pathological and genetic workup of a 25-year-old patient with this type of lymphoma and simultaneous papillary renal cell carcinoma. The patient developed both malignancies following extensive childhood immunosuppression and a kidney transplant.

View Article and Find Full Text PDF

Hemadsorption with CytoSorb®: focus on the latest experiences in cardiac surgery patients.

J Artif Organs

December 2024

Division of Cardiology, Ospedale Civile Maggiore Borgo Trento, Piazzale Stefani, Verona, (VR), Italy.

Cardiac surgery patients are potentially exposed to an acute inflammatory host response with a huge release of both pro- and anti-inflammatory cytokines both through intrinsic (e.g., tissue damage, endothelial injury) and extrinsic (e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!